Mounjaro Vs Wegovy: Which Should You Choose? - Guide | Cured Pharmacy

Mounjaro Vs Wegovy: Which Should You Choose?

WEIGHT LOSS · 21 MIN READ
Written by Cured Pharmacy
Published on 14 August 2026
★★★★★ Judge.me Reviews
Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

Featured Product

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

From£145.00£124.99 UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment → ✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 14 August 2026

If you have been scrolling through weight loss options and found yourself stuck between two names that keep appearing everywhere, you are not alone. Thousands of people across the UK are asking the same question every single day, and the answer is not as simple as picking the one with the flashier advert. Both medications have genuinely changed lives, reduced serious health risks, and helped people lose weight in ways that diet and exercise alone simply could not achieve for them. But they work differently, they suit different people, and the choice between them really does matter for your long term results and your wellbeing.

Summary

Choosing between these two leading weight loss injections comes down to your individual health profile, how much weight you need to lose, and what your prescriber recommends after a thorough assessment. Both are clinically proven, NHS acknowledged treatments with strong safety records.

  • Mounjaro (tirzepatide) targets two gut hormones, GIP and GLP-1, while Wegovy (semaglutide) targets one, GLP-1 only.
  • Clinical trials show Mounjaro typically produces greater average weight loss than Wegovy over comparable timeframes.
  • Both require a weekly injection and are titrated up slowly from a starting dose.
  • Side effects overlap significantly but vary in intensity between individuals.
  • Your eligibility, existing conditions, and personal goals should guide your final choice alongside professional medical advice.

Table of Contents

  1. How Mounjaro and Wegovy Actually Work
  2. Weight Loss Results: What the Evidence Really Shows
  3. Side Effects and Tolerability: An Honest Comparison
  4. Who Qualifies for Each Medication in the UK
  5. Cost, Access, and Getting Started
  6. Mounjaro vs Wegovy: Which Should You Choose? Making the Final Call
  7. Key Takeaways
  8. When to Seek Professional Advice
  9. Scientific References
  10. FAQs

How Mounjaro and Wegovy Actually Work

Weight Loss Timeline Estimator

Enter your details below to estimate your potential weight loss journey on Mounjaro or Wegovy. This is an educational guide only, not medical advice.




Understanding the mechanism behind each drug helps explain why one might suit you better than the other. Wegovy contains semaglutide, a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after eating. It tells your brain you are full, slows the emptying of your stomach, and reduces the urge to eat. Semaglutide mimics this hormone at a much higher intensity than your body naturally produces, which is why it produces meaningful appetite suppression and weight reduction.

Mounjaro contains tirzepatide, which is often described as a dual agonist. It activates both GLP-1 receptors and GIP receptors. GIP, or glucose dependent insulinotropic polypeptide, is another gut hormone involved in fat storage, energy balance, and insulin regulation. By targeting two pathways simultaneously, tirzepatide appears to produce a more powerful signal, both suppressing appetite and altering the way the body stores and uses fat. This dual action is widely considered the reason Mounjaro tends to show stronger average weight loss in trials.

  • Wegovy acts on one hormone pathway: GLP-1 only
  • Mounjaro acts on two hormone pathways: GLP-1 and GIP
  • Both slow gastric emptying, reduce hunger signals, and improve blood sugar regulation
  • Both are administered as a weekly subcutaneous injection
  • Both require a gradual dose escalation over several months to reach the therapeutic maintenance dose

When comparing these treatments through the lens of weight loss options available in the UK, understanding the pharmacology genuinely helps you have a more informed conversation with your prescriber rather than just choosing based on name recognition alone.

Weight Loss Results: What the Evidence Really Shows

This is where things get really interesting, and where the data can feel almost too good to be true if you have spent years struggling with your weight. The SURMOUNT-1 trial, which examined tirzepatide in people with obesity without type 2 diabetes, found that participants on the highest dose (15mg) lost an average of 22.5% of their body weight over 72 weeks. For someone weighing 120kg, that is approximately 27kg. The STEP-1 trial for semaglutide 2.4mg found an average weight loss of around 14.9% of body weight over 68 weeks. Both of these figures are extraordinary compared to older weight loss medications, but the gap between them is significant enough to matter for many patients.

It is important to note that these are averages. Some participants on Wegovy lost considerably more than 15%, and some on Mounjaro lost less than 22%. Individual response varies based on genetics, metabolic rate, adherence to lifestyle changes, and baseline health conditions. What the clinical data does consistently show is that tirzepatide produces a statistically and clinically meaningful greater weight loss on average than semaglutide, particularly at higher doses.

  • SURMOUNT-1 (Mounjaro): average 22.5% body weight loss at 15mg over 72 weeks
  • STEP-1 (Wegovy): average 14.9% body weight loss at 2.4mg over 68 weeks
  • Head to head trial SURMOUNT-5 (2025) confirmed Mounjaro's superiority in direct comparison
  • Both outperform older medications like orlistat significantly
  • Lifestyle support alongside medication dramatically improves outcomes for both

In 2026, updated real world UK prescribing data is beginning to reflect what the trials suggested: patients on Mounjaro are reporting larger total weight losses, though Wegovy continues to be highly effective and better tolerated by some individuals with specific digestive sensitivities. The right result is the one that is sustainable for you personally, not the one that looks best on a graph.

Side Effects and Tolerability: An Honest Comparison

Nobody likes talking about side effects, but ignoring them would be doing you a disservice. Both medications share a very similar side effect profile because they both act on GLP-1 pathways. The most commonly reported effects are nausea, vomiting, diarrhoea, constipation, and stomach discomfort. These tend to be most pronounced when doses are first increased and typically reduce as your body adjusts over several weeks.

In clinical trials, nausea was reported by roughly 44% of Wegovy users and around 31 to 45% of Mounjaro users depending on the dose. Vomiting and diarrhoea were similarly common across both groups. Importantly, severe adverse events leading to discontinuation were relatively rare in both trials, though higher doses of both medications were associated with more gastrointestinal complaints. There is also a small but notable risk of pancreatitis with both medications, which is why a thorough prescriber assessment before starting is non-negotiable.

  • Nausea is the most frequently reported side effect for both medications
  • Side effects are usually most intense during the first few weeks of each dose increase
  • Eating smaller, lower fat meals significantly helps manage gastrointestinal symptoms
  • Both medications carry contraindications including personal or family history of medullary thyroid carcinoma
  • Neither medication should be used during pregnancy

Some patients find that Wegovy is slightly easier on the stomach at equivalent stages of treatment, though this is anecdotal and highly individual. If you have had issues with nausea on Wegovy and are considering switching, it is worth discussing with your prescriber rather than assuming Mounjaro will be gentler. For some people, it may not be. Managing side effects well is one area where ongoing clinical support makes a real difference, which is why working through a medically supervised service matters.

Who Qualifies for Each Medication in the UK

Eligibility criteria differ slightly between the two medications and the route through which you access them, whether via the NHS or a private prescriber. On the NHS, access to both medications remains limited in 2026, tied largely to specialist weight management services and specific criteria around BMI and comorbidities. Through a private service, access is somewhat broader, though responsible prescribers still apply clinical thresholds.

For Wegovy, NICE guidance recommends it for adults with a BMI of 35 or above alongside at least one weight related comorbidity such as type 2 diabetes, hypertension, or sleep apnoea. It can also be considered for adults with a BMI of 30 to 34.9 in certain clinical contexts. For Mounjaro, NICE's 2023 and subsequently updated guidance recommends it for adults with a BMI of 35 or above with at least one weight related comorbidity, though it was also originally licensed for type 2 diabetes management at lower BMI thresholds.

  • NHS access to both is through specialist weight management pathways in most cases
  • Private prescribers can offer both medications within responsible clinical guidelines
  • Minimum BMI thresholds apply: typically 30 with comorbidities or 35 without
  • Mounjaro was originally licensed for type 2 diabetes, which may affect prescribing decisions in certain cases
  • A full medical history review is required before either medication is prescribed

You can explore your eligibility for weight loss treatment in the UK through a proper online assessment that reviews your health history before any prescription is issued. This kind of structured process protects you and ensures you receive the most appropriate treatment for your specific situation.

Cost, Access, and Getting Started

Cost is one of the most practical factors for most people, and it is one where being well informed saves you from making decisions based on incomplete information. On the NHS, both medications are effectively free at the point of access if you qualify through a specialist pathway, though waiting lists can be lengthy. Through private pharmacy or telehealth services, costs vary considerably depending on the dose and the provider.

Wegovy pricing in the UK typically ranges from around £159 to £299 per month depending on dose and provider. Mounjaro is generally available from around £125 to £249 per month privately. Both prices have been gradually becoming more competitive as supply has stabilised through 2025 and into 2026. When choosing a private provider, the price is only one part of the picture. The quality of the prescriber assessment, ongoing clinical monitoring, the ability to adjust your dose, and the support available if you experience side effects all matter enormously.

Cured Pharmacy stands out in this space for a number of reasons. The prescribing process is genuinely thorough, conducted by UK registered clinicians who review your full medical history rather than rubber stamping a questionnaire. Delivery is discreet, fast, and reliable. Mounjaro is available from £124.99, which includes free private prescription. New patients can also use the discount code FIRST20 to save £20 on their first order, making it one of the most affordable entry points for supervised private weight loss treatment in the UK right now. The platform is transparent, the pricing is competitive, and the clinical oversight is real rather than performative.

  • NHS access is free but often involves waiting lists and specialist referral requirements
  • Private Mounjaro from Cured Pharmacy starts from £124.99 with free prescription included
  • Use code FIRST20 to save £20 as a new patient at Cured Pharmacy
  • Always check that your provider uses registered UK prescribers, not automated systems
  • Ongoing monitoring and dose adjustment support should be part of any responsible private service

If you are considering Wegovy (semaglutide) weight loss injections specifically, Cured Pharmacy offers these through the same medically supervised route, with a full online assessment ensuring that your treatment is appropriate for your health profile.

Mounjaro vs Wegovy: Which Should You Choose? Making the Final Call

This is the question everyone ultimately wants answered, and if you have read this far, you deserve a straight, evidence informed response rather than a diplomatic non-answer. Mounjaro vs Wegovy: Which Should You Choose? depends fundamentally on what you are trying to achieve, your medical history, and how your body responds to treatment. There is no universally correct answer, but there are patterns in the evidence that are worth knowing.

If you have a significant amount of weight to lose, say 25kg or more, and you have no contraindications to tirzepatide, Mounjaro is likely to offer the strongest average results based on current clinical evidence. The SURMOUNT-5 trial, published in early 2025, directly compared tirzepatide and semaglutide in adults with obesity and found that those on tirzepatide lost approximately 47% more relative weight than those on semaglutide over a comparable period. That is a meaningful real world difference, not just a statistical curiosity.

However, Wegovy may be preferable if you have already had a good initial response to a lower dose GLP-1 medication and found it well tolerated, if your prescriber has specific clinical reasons to recommend it, or if you are managing type 2 diabetes in a context where semaglutide's established cardiovascular benefits (demonstrated in the SELECT and SUSTAIN trials) are particularly relevant to your care plan. Both medications reduce cardiovascular risk in people with obesity, but the cardiovascular outcome data for semaglutide is more extensive at this point.

  • Choose Mounjaro if you have a larger weight loss goal and no contraindications to tirzepatide
  • Consider Wegovy if you have established cardiovascular disease and your cardiologist is involved in your care
  • Neither medication works optimally without dietary changes and increased physical activity
  • If you try one and it does not suit you, switching under prescriber guidance is a legitimate option
  • Do not choose based on social media testimonials alone; clinical assessment trumps anecdote every time

It is also worth acknowledging the emotional weight of this decision. Many people come to these medications after years of failed diets, metabolic challenges, and being told to simply eat less and move more. Both Mounjaro and Wegovy represent a genuine pharmacological shift in what is possible for weight management, and neither choice is a wrong one if made with proper medical support. The best medication is the one you can access safely, tolerate well, and maintain consistently.

Mounjaro vs Wegovy Side by Side: Full Comparison Table

Feature Mounjaro (Tirzepatide) Wegovy (Semaglutide)
Drug class Dual GIP/GLP-1 receptor agonist GLP-1 receptor agonist
Manufacturer Eli Lilly Novo Nordisk
Licensed for obesity in UK Yes (MHRA licensed for weight management) Yes (MHRA licensed for weight management)
Starting dose 2.5mg weekly 0.25mg weekly
Maintenance dose 5mg, 10mg, or 15mg weekly 1mg, 1.7mg, or 2.4mg weekly
Average weight loss (trial peak) ~22.5% body weight (SURMOUNT-1) ~14.9% body weight (STEP-1)
Administration Weekly subcutaneous injection (KwikPen) Weekly subcutaneous injection (autoinjector pen)
Common side effects Nausea, diarrhoea, vomiting, constipation Nausea, diarrhoea, vomiting, constipation
Cardiovascular outcome data SURPASS-CVOT ongoing/emerging Extensive (SELECT, SUSTAIN trials)
NICE recommended BMI threshold 35+ with comorbidity (or 30+ in some pathways) 35+ with comorbidity (or 30+ in some pathways)
Private cost (approximate, UK 2026) From £124.99 at Cured Pharmacy From ~£159 at various UK providers
Use in type 2 diabetes Yes, licensed for T2D management Yes, licensed for T2D management (Ozempic brand)
Use in pregnancy Not recommended Not recommended

Key Takeaways

  • Mounjaro (tirzepatide) targets two gut hormone receptors and produces greater average weight loss in clinical trials compared to Wegovy (semaglutide).
  • Wegovy has a longer track record for cardiovascular risk reduction and may be preferred in certain high risk cardiac profiles.
  • Side effects are similar for both: nausea and gastrointestinal discomfort are the most common, particularly during dose escalation.
  • Eligibility for both medications in the UK is based on BMI and the presence of weight related comorbidities.
  • Cured Pharmacy offers Mounjaro from £124.99 with UK registered prescribers, discreet delivery, and the code FIRST20 to save £20 as a new patient.

When to Seek Professional Advice

You should always speak to a qualified healthcare professional before starting either medication, but there are specific situations where professional input is especially important rather than optional. If you have a personal or family history of thyroid cancer, pancreatitis, gallbladder disease, severe kidney disease, or eating disorders, these conditions must be disclosed and assessed before any prescription is considered. Similarly, if you are taking medications that interact with GLP-1 receptor agonists, particularly insulin or sulfonylureas if you have type 2 diabetes, your management plan may need adjustment.

If you experience severe abdominal pain that radiates to your back, persistent vomiting, or rapid heart rate after starting either medication, seek medical attention promptly. These could indicate pancreatitis or another serious adverse reaction. Always ensure you are using a service with genuine prescriber access, not simply a chatbot that processes your answers without clinical review. The distinction matters for your safety.

Support alongside medical treatment is also worth considering. Nutritional guidance, physical activity support, and psychological support for emotional eating can all meaningfully improve your outcomes. Weight loss is rarely just a biological problem; it is often a complex interaction between hormones, habits, mental health, and environment. The best outcomes happen when medication is one component of a broader supported approach.

If you are also exploring general health support during your weight loss journey, maintaining good nutrition and micronutrient intake matters. You may want to look at weight loss support products at Cured Pharmacy as part of a comprehensive health approach. Additionally, if you are concerned about joint discomfort that sometimes accompanies rapid weight changes, joint pain support products are available to complement your progress.

Scientific References

  1. NICE Technology Appraisal TA875: Semaglutide for managing overweight and obesity, NICE, 2023 [Accessed 14 August 2026]
  2. NICE Technology Appraisal TA1026: Tirzepatide for managing overweight and obesity in adults, NICE, 2024 [Accessed 14 August 2026]
  3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity, New England Journal of Medicine, 2022 [Accessed 14 August 2026]
  4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1), New England Journal of Medicine, 2021 [Accessed 14 August 2026]
  5. SURMOUNT-5 trial: Tirzepatide vs semaglutide in adults with obesity, The Lancet Diabetes and Endocrinology, 2025 [Accessed 14 August 2026]
  6. MHRA: Mounjaro (tirzepatide) UK product licensing information, MHRA, 2023 [Accessed 14 August 2026]
  7. Electronic Medicines Compendium (EMC): Wegovy SmPC, Novo Nordisk, 2023 [Accessed 14 August 2026]
  8. Electronic Medicines Compendium (EMC): Mounjaro SmPC, Eli Lilly, 2023 [Accessed 14 August 2026]
  9. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial), New England Journal of Medicine, 2023 [Accessed 14 August 2026]
  10. Sattar N et al. Tirzepatide for treatment of obesity and metabolic risk: review of clinical evidence, BMJ, 2023 [Accessed 14 August 2026]
  11. Diabetes UK: GLP-1 analogues and their role in diabetes and weight management, Diabetes UK, 2024 [Accessed 14 August 2026]
  12. British National Formulary (BNF): Semaglutide prescribing information, NICE/BNF, 2024 [Accessed 14 August 2026]
  13. British National Formulary (BNF): Tirzepatide prescribing information, NICE/BNF, 2024 [Accessed 14 August 2026]
  14. NHS: Obesity treatment overview including pharmacological options, NHS, 2024 [Accessed 14 August 2026]
  15. Davies M et al. Semaglutide 2.4mg once a week in adults with overweight or obesity and type 2 diabetes (STEP-2), The Lancet, 2021 [Accessed 14 August 2026]
  16. SURMOUNT-1 clinical trial registration: Tirzepatide obesity trial, ClinicalTrials.gov, 2021 [Accessed 14 August 2026]

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My AssessmentReturning Customer?Log In to Your Account

Frequently Asked Questions

How long does it take to see weight loss results on Mounjaro or Wegovy?

How long it takes to see results on Mounjaro or Wegovy depends on the individual, but most people notice measurable weight loss within the first 4 to 8 weeks of treatment. Significant results typically become apparent between weeks 12 and 24 as the dose is gradually increased to the therapeutic maintenance level. Full results are usually assessed at 52 to 72 weeks.

Is it safe to switch from Wegovy to Mounjaro if I am not losing enough weight?

Switching from Wegovy to Mounjaro is possible if you are not achieving sufficient results, but this must be done under prescriber guidance. Switching between GLP-1 based medications requires careful dose adjustment and monitoring to manage potential side effects. A prescriber will assess whether switching is appropriate based on your response, tolerance, and overall health profile.

Can you take Mounjaro or Wegovy if you have type 2 diabetes?

Both Mounjaro and Wegovy can be used in people with type 2 diabetes, and both were originally trialled in diabetic populations before receiving obesity licences. Mounjaro is specifically licensed for type 2 diabetes management under the name Mounjaro, while semaglutide for diabetes is prescribed as Ozempic. Your prescriber will adjust other diabetes medications, particularly insulin, to reduce hypoglycaemia risk.

What is the starting dose of Mounjaro compared to Wegovy?

The starting dose of Mounjaro is 2.5mg once weekly for the first four weeks, before increasing to 5mg. Wegovy starts at 0.25mg once weekly for four weeks, stepping up gradually to 2.4mg as the maintenance dose. Both medications use a slow titration schedule designed to minimise gastrointestinal side effects during the adjustment period.

Back to blog